Crescita Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Crescita Therapeutics Inc. (CRRTF) is a commercial dermatology company with in-house research, development and manufacturing capabilities that provides prescription and non-prescription skincare products for the treatment and care of skin conditions, diseases and their symptoms; its core offerings include premium brands such as Pliaglis, a topical anesthetic utilizing proprietary Multiplexed Molecular Penetration Enhancers and DuraPeel drug delivery platforms, Alyria, Laboratoire Dr Renaud, Pro-Derm and Aquafolia dermocosmetics; the company operates through three segments encompassing Commercial Skincare for manufacturing and sales of non-prescription products, Licensing and Royalties for prescription product commercialization, and Manufacturing and Services for topical product development and contract production. Founded in 2016 and headquartered in Laval, Quebec, Canada, with prior facilities in Mississauga, Ontario, Crescita Therapeutics conducts operations primarily in Canada and the United States, with international reach in Europe, South America and pending Asia via partnerships. Recent developments include the June 2024 acquisition of non-real estate assets from Occy Laboratoire Inc. for $0.9 million to expand dermocosmetic offerings and client base; the July 2024 amendment to its contract manufacturing supply agreement securing minimum annual US$2.5 million commitments over four years from a global skincare client and US$10 million total; a five-year exclusive manufacturing and supply agreement in July 2024 with a leading Canadian healthcare provider for sanitary products like hand sanitizer and lotion targeting publicly funded organizations with potential annual revenues up to $6.0 million; termination of the Croma Pharma licensing agreement in Q2 2025 yielding a €575,000 one-time payment and regaining full commercialization rights to Pliaglis in nine markets including Germany, the UK and Brazil; a new U.S. distribution agreement for Pliaglis relaunch anticipated in 2025 via IPG Pharmaceuticals; and exploration of a Juyou Bio-Technology partnership in China pending regulatory approval.
Knight Announces Early Warning Filing Regarding Shares of Crescita
Crescita Therapeutics Inc. Announces Closing of Arrangement
Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv
Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement
Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings
Crescita Reports First Quarter 2026 Results
Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings
Crescita Reports Q4 and Fiscal 2025 Results
Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium
Crescita Reports Third Quarter 2025 Results
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
Crescita Reports First Quarter 2025 Results
Crescita Reports Third Quarter 2024 Results
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Crescita Reports Second Quarter 2024 Results
Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Crescita Reports Q4 and Fiscal 2023 Results
Crescita Reports Third Quarter 2023 Results